

Patients' and consumers' organisation funding sources

NAME OF ORGANISATION: Myeloma Patients Europe (MPE)

YEAR: 2022

MPE Industry ¹ related income ²		
Name of company/ funder	Amount of income	% of overall organisation's income
Abbvie	5.420 €	0,4%
Amgen	35.000 €	2,9%
Binding Site	11.500 €	0,9%
Bristol Myers Squibb	146.146 €	12,0%
GSK	97.152 €	8,0%
Janssen	197.347 €	16,3%

¹ Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

² This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Novartis	65.153 €	5,4%
Oncopeptides	1.000 €	0,1%
Pfizer	226.880 €	18,7%
Prothena	5.000 €	0,4%
Roche	65.821 €	5,4%
Sandoz	15.000 €	1,2%
Sanofi	145.940 €	12,0%
Sebia	8.800 €	0,7%
SkylineDx	1.000 €	0,1%
Takeda	128.895 €	10,6%
Subtotal:	1.156.054 €	95,3%

MPE Non-industry related income – Public Funding

Source of funding ³	Amount of income	% of overall organisation's income
IMI SISAQoL	42.168 €	3,5%
IMI Harmony	5.116 €	0,4%
Subtotal:	47.284 €	3,9%

³ E.g. membership fees, donations.

MPE Non-industry related income		
CDDF	650 €	0,1%
EHA	962 €	0,1%
Evolution House	200 €	0,0%
HEM-CAB	1.589 €	0,1%
HTAi	1.003 €	0,1%
Patvocates	192 €	0,0%
T2Evolve	1.000 €	0,1%
Refund - Non Industry (various)	1.398 €	0,1%
Refund - Social security contribution	2.838 €	0,2%
Subtotal:	9.832 €	0,8%
TOTAL⁴:	1.213.170 €	100,0%

⁴ In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Information required to be included on organisation's website	Please include links below:
<ul style="list-style-type: none"> Funding sources: 	https://www.mpeurope.org/about-mpe/funding-sources/
<ul style="list-style-type: none"> Overall proportion of industry and non-industry: 	Industry: 95,3 %; Non-Industry incl. Public Funding: 4,7 %
<ul style="list-style-type: none"> Percentage of the highest contribution from a single company: 	18,7 % of overall organizations income

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf